Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Nuvo Stories

2013-12-19 08:26:52

MISSISSAUGA, ON and MOSCOW, Dec. 19, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of products in the areas of topical pain and immunology, and NovaMedica LLC (NovaMedica), a Russian pharmaceutical company, today announced that they have signed a supply and distribution agreement providing NovaMedica the exclusive rights to market and sell Nuvo's Pennsaid 1.5% and Pennsaid 2% products in Russia and some of the...

2013-11-21 08:26:16

VANCOUVER, Nov. 21, 2013 /PRNewswire/ - Moshe Safdie has had a storied career as an architect. The Israeli-born, Canadian-raised, and Boston-based practitioner is the cover subject for NUVO's 15th anniversary issue, on newsstands now. From his elegant, ivy-covered office studio in Massachusetts, the silver-haired architect spent time with contributor Christopher Hume recounting his near 50-year career in pursuit of "inherent buildability". Writes Hume: "Safdie can unquestionably...

2013-08-21 08:25:33

MISSISSAUGA, ON, Aug. 21, 2013 /PRNewswire/ - Nuvo Research Inc. (Nuvo) (TSX:NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that the Company has commenced legal action against Mallinckrodt Inc. (Mallinckrodt) by filing a Complaint in the United States District Court for the Southern District of New York. The Complaint asserts...

2013-07-10 20:22:10

MISSISSAUGA, ON and MONTREAL, July 10, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, and Paladin Labs Inc. (TSX: PLB), a leading specialty pharmaceutical company today announced that they have completed the amended loan arrangements (the "Loan") the details of which were previously announced on June...

2013-06-18 16:25:15

MISSISSAUGA, ON, June 18, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain announced today that, at its 2013 annual and special meeting of shareholders held in Mississauga, all nominees listed in the management proxy circular dated May 1, 2013 were elected, by a show of hands, as directors of the Company. The detailed results of the votes by proxy are as follows:...

2013-06-17 16:25:54

MISSISSAUGA, ON and MONTREAL, QC, June 17, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, and Paladin Labs Inc. (TSX: PLB), a leading specialty pharmaceutical company today announced that they have amended their loan arrangements (the "Loan") originally agreed to in May 2012.  In May of 2012, Nuvo...

2013-05-09 08:30:24

MISSISSAUGA, ON, May 9, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that the European Patent Office has issued a notice of Intention to Grant a European Patent that provides protection for the Company's PENNSAID(®) 2% product. Upon grant by the European Patent Office, the patent can be officially validated in over 37 European countries....

2013-05-07 08:30:53

MISSISSAUGA, ON, May 7, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) (the "Company" or "Nuvo"), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced that it will proceed with its proposed share consolidation (the "Consolidation"), as approved by the shareholders of Nuvo at the annual and special meeting held on May 15, 2012, on the basis...

2013-03-18 08:28:37

MISSISSAUGA, ON, March 18, 2013 /PRNewswire/ - Nuvo Research Inc. (Nuvo) (TSX:NRI) announced today that a Question and Answer document has been posted on its website to provide additional information to Nuvo shareholders regarding the regulatory status of Pennsaid 2% in the United States. Follow this link to access the document - Pennsaid 2% Q&A. Pennsaid 2% Pennsaid 2% is the follow-on product to original Pennsaid, a topical non-steroidal anti-inflammatory drug (NSAID). ...

2012-10-29 15:26:30

- Third quarter results to be released after market close on October 31, 2012 - MISSISSAUGA, Oct. 29, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced it will host a conference call on Thursday, November 1, 2012 at 8:30 a.m. (ET) to discuss its 2012 third quarter financial results....